NIH R01 · 2025
Systemic and gastrointestinal targeted CDPK1 inhibitors for cryptosporidiosis
ABSTRACT Cryptosporidium species, including C. hominis and C. parvum, are protozoan parasites that present a significant health threat, particularly to young children and immunocompromised adults. These organisms have the potential to be deliberately introduced into the water supply, making them a CDC class B bioterrorism agent. Current treatment options for Cryptosporidium infections are very limited to one FDA-approved drug that is not effective in young children and immunocompromised adults. In addition, vaccines are unavailable. Calcium dependent protein kinase 1 (CDPK1) has emerged as a promising target for treating cryptosporidiosis, since silencing this protein significantly reduces…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.